Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL
A phase 2 trial of Olvimulogene nanivacirepvec, Nivolumab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Genelux Corporation, now recruiting.
Overview
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer is a phase 2 interventional study registered as NCT06463665 by Genelux Corporation, with 142 participants planned, started 2024-09-26 and due to reach its primary completion in 2027-02. Interventions recorded: Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel. Conditions listed: Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Shares Olvimulogene nanivacirepvec, Genelux.
- TrialBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Shares Cemiplimab, Atezolizumab, Nivolumab, Small-cell lung cancer.
- TrialBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati
Shares Atezolizumab, Durvalumab, Nivolumab, Small-cell lung cancer.
- TrialQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Shares Atezolizumab, Durvalumab, Nivolumab, Small-cell lung cancer.
- TrialA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Shares Docetaxel, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialTrial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Shares Docetaxel, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [
Shares Atezolizumab, Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.